Free tool
FAERS Monitor: Nutrilipid 10%
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019531 or its brand name (Nutrilipid 10%, Soybean Oil). Reports on generic versions are filed under their own applications.
Reports
680
Serious
356
52% of reports
Hospitalization
158
Death reported
67
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- chills134
- pyrexia133
- nausea83
- vomiting54
- chest discomfort45
- dyspnoea44
- palpitations34
- abdominal distension31
- rash29
- dizziness28
- pruritus27
- abdominal pain23
- off label use22
- hyperhidrosis19
- anaemia17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 4 |
| 2014 | 1 |
| 2015 | 9 |
| 2016 | 43 |
| 2017 | 48 |
| 2018 | 87 |
| 2019 | 147 |
| 2020 | 81 |
| 2021 | 23 |
| 2022 | 48 |
| 2023 | 73 |
| 2024 | 59 |
| 2025 | 32 |
| 2026 | 13 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,479 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chillsSignal | 134 | 35.4 | 30.4 | 4,464 |
| chest discomfortSignal | 45 | 13.6 | 10.3 | 515 |
| pyrexiaSignal | 133 | 11.9 | 10.2 | 1,338 |
| abdominal distensionSignal | 31 | 9.2 | 6.5 | 219 |
| palpitationsSignal | 34 | 9.0 | 6.5 | 235 |
| hyperhidrosisSignal | 19 | 4.6 | 2.9 | 50 |
| vomitingSignal | 54 | 3.6 | 2.8 | 99 |
| nauseaSignal | 83 | 3.2 | 2.7 | 132 |
| abdominal painSignal | 23 | 3.1 | 2.0 | 30 |
| anaemiaSignal | 17 | 2.8 | 1.7 | 17 |
| dyspnoeaSignal | 44 | 2.4 | 1.8 | 36 |
| pruritusSignal | 27 | 2.2 | 1.5 | 16 |
| rashSignal | 29 | 2.1 | 1.4 | 15 |
| dizziness | 28 | 1.7 | 1.2 | 8 |
| off label use | 22 | 0.8 | 0.5 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.